Ospedale Sandro Pertini, Roma
11
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Radial accEss Crossover for PErcutaneous Coronary Procedures And ouTcome: the REPEAT Study
Role: lead
RadiatiOn Dose Among Different EndOvascular Procedures: the RODEO Study
Role: lead
Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study
Role: collaborator
Enhanced Recovery and Patient Blood Management in Colorectal Surgery
Role: lead
The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes
Role: collaborator
Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)
Role: collaborator
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ENEMA ALOE VERA GEL IN ACTIVE ULCERATIVE PROCTOSIGMOIDITIS.
Role: lead
EXTended pRotective Curtain Under Table to Reduce Operator RAdiation Dose in Percutaneous Coronary Procedures
Role: lead
RAdiation Dose In percutANeuos Coronary Procedures Through Transradial Approach (RADIANT Observational Study)
Role: lead
RAdiation Dose In percutAneuos Coronary Procedures Through TransradIal apprOach Using Dedicated radiatioN Shields
Role: lead
Hand Grip Test and Transradial Coronary Procedures
Role: lead
All 11 trials loaded